These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 25703571)

  • 1. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
    Kim YR; Yang CS
    J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.
    Mehta K; Spaink HP; Ottenhoff THM; van der Graaf PH; van Hasselt JGC
    Trends Pharmacol Sci; 2022 Apr; 43(4):293-304. PubMed ID: 34916092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
    Park HE; Lee W; Shin MK; Shin SJ
    Front Immunol; 2021; 12():703060. PubMed ID: 34262571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TB drug development: immunology at the table.
    Nathan C; Barry CE
    Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Macrophage Response to
    Maphasa RE; Meyer M; Dube A
    Front Cell Infect Microbiol; 2020; 10():618414. PubMed ID: 33628745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis.
    Saini S; Gangwar A; Sharma R
    Microbiol Res; 2023 Oct; 275():127466. PubMed ID: 37531813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.
    Giraud-Gatineau A; Coya JM; Maure A; Biton A; Thomson M; Bernard EM; Marrec J; Gutierrez MG; Larrouy-Maumus G; Brosch R; Gicquel B; Tailleux L
    Elife; 2020 May; 9():. PubMed ID: 32369020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-Directed Therapeutics against Mycobacterial Infections.
    Tomioka H; Sano C; Tatano Y
    Curr Pharm Des; 2017; 23(18):2644-2656. PubMed ID: 27908271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against
    Palucci I; Maulucci G; De Maio F; Sali M; Romagnoli A; Petrone L; Fimia GM; Sanguinetti M; Goletti D; De Spirito M; Piacentini M; Delogu G
    Front Immunol; 2019; 10():3042. PubMed ID: 32038614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remembering the Host in Tuberculosis Drug Development.
    Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
    J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clofazimine inhibits innate immunity against
    Li X; Luo X; Wang B; Fu L; Chen X; Lu Y
    mSphere; 2024 Aug; 9(8):e0025424. PubMed ID: 39046230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating Iron for Metabolic Support of TB Host Defense.
    Phelan JJ; Basdeo SA; Tazoll SC; McGivern S; Saborido JR; Keane J
    Front Immunol; 2018; 9():2296. PubMed ID: 30374347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine and lipid mediator networks in tuberculosis.
    Mayer-Barber KD; Sher A
    Immunol Rev; 2015 Mar; 264(1):264-75. PubMed ID: 25703565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
    Tomioka H; Tatano Y; Sano C; Shimizu T
    J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.